EC green light for Vumerity as oral therapy for relapsing MS

17 November 2021
biogen_big

The European Commission (EC) has granted marketing authorization for Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).

Developed and marketed by US biotech major Biogen (Nasdaq: BIIB), Vumerity is a next-generation fumarate that offers the convenience of an oral medication with the established efficacy and well-characterized safety of Biogen’s Tecfidera (dimethyl fumarate). Globally, an estimated 2.8 million people live with MS, with more than 1 million people in Europe living with the disease.

Vumerity generated sales pf $120 million sales in the third quarter of this year, up from $14 million in the like 2020 period. Sales of Tecfidera, which is now facing generic competition as a West Virginia federal court invalidated a key patent on the drug in June last year, were $499 million in the last quarter, down from $953 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical